The Source Blog
Recent Action in Pharmaceuticals
Introduced: 2025 Status:
This bill introduces new regulations for health insurance plans and drug discount coupons in Utah, focusing on how cost-sharing requirements are calculated and applied. The bill defines key terms like “biosimilar” (a biological product highly […]
HB 0519 – Utah
Introduced: 2025 Status:
This bill addresses the 340B drug discount program by establishing new regulations for pharmaceutical manufacturers. The 340B program allows certain healthcare providers, such as hospitals and community health centers, to purchase prescription drugs at discounted […]
HB 1041 – Virginia
Introduced: 2025 Status: In Process
This bill addresses several key provisions related to health insurance, pharmacy benefits managers (PBMs), and prescription drug cost-sharing. The bill requires that an enrollee’s out-of-pocket costs (defined cost-sharing) for prescription drugs be calculated at the […]
HB 2380 – Virginia
Introduced: 2025 Status: In Process
This bill establishes a Pharmacy Benefits Manager (PBM) and Third-Party Administrator Oversight Work Group to address prescription drug costs and healthcare expenses in Virginia. The Work Group, convened by the Secretary of Health and Human […]
HB 2831 – West Virginia
Introduced: 2025 Status: In Process
This bill creates the West Virginia Prescription Drug Affordability Board (the Board), a new state entity designed to address high prescription drug costs. The Board will consist of five members appointed by various state officials, […]
SB 62 – New Mexico
Introduced: 2025 Status: In Process
This bill amends the Pharmacy Benefits Manager (PBM) Regulation Act to introduce more stringent oversight and transparency for pharmacy benefits managers. The legislation defines key terms such as “bona fide service fee” as a flat […]
SB 503 – New Mexico
Introduced: 2025 Status: In Process
This bill amends New Mexico’s Pharmacy Benefits Manager (PBM) Regulation Act to introduce several new definitions and prohibit certain practices by pharmacy benefits managers. The bill defines new terms like “patient steering,” which includes directing […]
Next | See all Legislation Records
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in […]
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of […]
In re: Flonase Antitrust Litigation – Louisiana, Pennsylvania
District Court: Eastern District of Pennsylvania Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline […]
Mohr-Lercara v. Oxford Health Ins., Inc. – New York
District Court: Southern District of New York Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that […]
In Re UnitedHealth Group PBM Litigation – Minnesota
District Court: District of Minnesota Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay […]
Negron v. Cigna and OptumRx – Connecticut
District Court: District of Connecticut Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription […]
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims […]
Previous | Next | See all Litigation Records
News & Opinions
Articles & Reports
Health Affairs June 3, 2025
Health Affairs May 27, 2025
Journal of Healthcare Provision and Public Health May 14, 2025
Trends in Pharmaceuticals
State Pharmaceutical Legislation
Click on highlighted states to see all legislative action to regulate pharmaceutical price and competition in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
2019 Drug Pricing Transparency Legislation
Pharmaceutical price transparency legislation requires disclosures from drug manufacturers and insurers to help lawmakers and the public better understand how drugs are priced and how those prices affect insurance premiums. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmaceutical Rate-Setting Legislation
Rate setting legislation either establishes the price of a prescription drug or sets the maximum amount a payer can pay for a drug. Click on highlighted states to see rate-setting legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Importation Legislation
Click on highlighted states to see drug importation legislation considered or enacted in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Drug Price Gouging Prohibition Legislation
Price gouging prohibitions typically empower the state Attorney General to act if the price of a drug is raised above a threshold. Click on highlighted states to see legislation considered in the 2019 session. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered
2019 Pharmacy Benefit Manager Regulation Legislation
Legislation to regulate Pharmacy Benefit Managers (PBMs) typically include provisions that 1) require PBMs to register with the state, 2) mandate disclosures by PBMs, or 3) prevent PBMs from incentivizing the use of mail-order pharmacies. Click to see 2018 trends for a side-by-side comparison.
-
Key:
- Enacted
- Considered